New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
07:06 EDTCCXIChemoCentryx CCX168 granted orphan designation in ANCA-associated diseases
ChemoCentryx confirmed that the FDA has granted orphan-drug designation for CCX168, an orally administered inhibitor that targets the receptor for the complement protein known as C5a. The designation is for the treatment of anti-neutrophil cytoplasmic autoantibodies, or ANCA, -associated vasculitides. CCX168 is currently in the third step of the CLEAR clinical trial in patients with ANCA-associated vasculitis. CEO Thomas Schall said, "We believe this designation may facilitate an expeditious clinical development path for CCX168, and is emblematic of our deep commitment to supporting the community of patients with ANCA-associated vasculitis."
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
13:04 EDTCCXIOn The Fly: Midday Wrap
Subscribe for More Information
09:13 EDTCCXIOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Adobe (ADBE), up 5.5% after reporting first quarter results and that it will acquire Fotolia for approximately $800 in cash. ALSO HIGHER: ChemoCentryx (CCXI), up 107.1% after Phase II clinical trial in diabetic nephropathy with CCX140 met its primary endpoint... Oncothyreon (ONTY), up 15.8% after announcing exclusive agreement with Array BioPharma (ARRY)... Talisman Energy (TLM), up 24.4% after a report that Repsol (REPYY) is preparing to make a C$6.00 per share bid... GoPro (GPRO), up 4.4% after being upgraded to Overweight from Neutral at JPMorgan. LOWER: Emerald Oil (EOX), down 18% after cutting fiscal 2015 guidance, naming new COO, and providing an updated fiscal 2015 development plan... Goodrich Petroleum (GDP), down 8.2% after being downgraded to Underweight from Overweight at JPMorgan... MEI Pharma (MEIP), down 3.9% after 10M share Secondary priced at $4.00... Heritage-Crystal Clean (HCCI), down 6.6% after 3.1M share Secondary priced at $10.00.
09:03 EDTCCXIChemoCentryx up 107.1% after Phase II trial met primary endpoint
Subscribe for More Information
06:46 EDTCCXIChemoCentryx to host conference call
Subscribe for More Information
06:38 EDTCCXIChemoCentryx reports Phase II nephropathy with CCX140 trial met primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use